Showing posts with the label Endo International

Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada

IndustryPRwire - Endo International announced that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and …

Endo Launches Authorized Generic Version of Amitiza® (lubiprostone) Capsules in the United States

IndustryPRwire - Endo International announced that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first authorized generic versions of Mallinckrodt's Amit…

Endo Completes Acquisition of BioSpecifics

IndustryPRwire -- Endo International announced that it completed the previously announced acquisition of BioSpecifics Technologies Corp for $88.50 per share in an all-cash transaction, for an estima…

Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™

Endo International today announced it has agreed to acquire all of the outstanding shares of BioSpecifics Technologies Corp for $88.50 in cash per share, or an estimated enterprise value of approxim…
Subscribe Our Newsletter